3-氯吡嗪-2-羧酸乙酯 | 655247-45-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-氯吡嗪-2-羧酸乙酯
• 英文名称: 3-chloropyrazine-2-carboxylic acid ethyl ester
• 英文别名: ethyl 3-chloropyrazine-2-carboxylate；ethyl-3-chloropyrazine-2-carboxylate
• CAS: 655247-45-3
• 化学式: C₇H₇ClN₂O₂
• mdl: MFCD07371661
• 分子量: 186.598
• InChiKey: AZNJBCHPEMMGOL-UHFFFAOYSA-N

物化性质

• 沸点：
  265.0±35.0 °C(Predicted)
• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-chloro-pyrazine-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-chloro-pyrazine-2-carboxylate
CAS number: 655247-45-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7ClN2O2
Molecular weight: 186.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯吡嗪-2-羧酸乙酯 在 水 、 sodium carbonate 作用下， 以 甲醇 为溶剂， 生成 2-氯吡嗪-3-羧酸
  参考文献：
  名称：

  吡嗪羧酸衍生物：1H、13C和15N核磁共振谱研究

  摘要：

  核磁共振光谱研究是用 2-吡嗪羧酸的衍生物进行的。化学位移 (1H, 13C, 15N) 和耦合常数 (1H,1H; 13C,1H; 15N,1H) 的完整和明确分配是通过各种 1D 和 2D NMR 光谱技术的组合应用来实现的。13C,1H 自旋耦合常数的明确映射是通过具有选择性激发的 2D (δ,J) 长程 INEPT 光谱完成的。讨论了诸如 3-羟基-2-吡嗪羧酸的互变异构现象。版权所有 © 2009 John Wiley & Sons, Ltd.

  DOI：

  10.1002/mrc.2437
• 作为产物：
  描述：

  2-氯吡嗪-3-羧酸 在 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 3-氯吡嗪-2-羧酸乙酯
  参考文献：
  名称：

  发现和SAR的第一个临床阶段蛋白激酶CK2抑制剂5-（3-氯苯基氨基）苯并[ c ] [2,6]萘吡啶-8-羧酸（CX-4945）

  摘要：

  本文中，我们对CX-4945（25n）的发现进行了编年史，CX-4945是蛋白激酶CK2的一流的，口服可生物利用的ATP竞争性抑制剂，在癌症的临床试验中得到了证实。CK2长期以来一直被认为是主要的癌症药物靶标，因为CK2的失调和过度表达在促进癌症的生存和抗凋亡途径中起着重要的作用。这些生物学特性以及CK2的小ATP结合位点对选择性抑制剂设计的适用性，使我们开发出了新型的癌症治疗剂。导致25n（K i = 0.38 nM）的最优化是通过分子建模指导的，这表明25n的强结合由疏水相互作用，与Lys68形成的离子桥以及与铰链区的氢键结合而成。发现25n具有高度选择性，可跨物种口服生物利用（20-51％），并且在异种移植模型中有效。25n的发现将首次使CK2在人类中具有治疗靶向性。

  DOI：

  10.1021/jm101251q

文献信息

• Synthesis and structure–activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors
  作者：Xiaohu Ouyang、Xiaoling Chen、Evgueni L. Piatnitski、Alexander S. Kiselyov、Hai-Ying He、Yunyu Mao、Vatee Pattaropong、Yang Yu、Ki H. Kim、John Kincaid、Leon Smith、Wai C. Wong、Sui Ping Lee、Daniel L. Milligan、Asra Malikzay、James Fleming、Jason Gerlak、Dhanvanthri Deevi、Jacqueline F. Doody、Hui-Hsien Chiang、Sheetal N. Patel、Ying Wang、Robin L. Rolser、Paul Kussie、Marc Labelle、M. Carolina Tuma

  DOI：10.1016/j.bmcl.2005.08.056

  日期：2005.12

  triazole-containing chemical series was shown to inhibit tubulin polymerization and cause cell cycle arrest in A431 cancer cells with EC(50) values in the single digit nanomolar range. Binding experiments demonstrated that representative active compounds of this class compete with colchicine for its binding site on tubulin. The syntheses and structure-activity relationship studies for the triazole derivatives

  一种新型的含有三唑的化学系列显示抑制微管蛋白聚合并导致细胞周期停滞在EC（50）值在一位数纳摩尔范围内的A431癌细胞。结合实验表明，这类代表性的活性化合物与秋水仙碱竞争其在微管蛋白上的结合位点。本文描述了三唑衍生物的合成和结构-活性关系研究。
• [EN] POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER<br/>[FR] AMIDES POLYCYCLIQUES UTILISÉS EN TANT QUE MODULATEURS D'UBE2K POUR LE TRAITEMENT DU CANCER
  申请人：BERG LLC

  公开号：WO2021138540A1

  公开（公告）日：2021-07-08

  Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

  提供的是Formula (I)的化合物及其药用盐和组合物，可用于治疗与UBE2K调节相关的疾病。
• 杂芳基酰胺类衍生物及其作为TGR5激动剂的应用
  申请人：山东轩竹医药科技有限公司

  公开号：CN106317027A

  公开（公告）日：2017-01-11

  本发明属于医药技术领域，具体涉及式(I)所示的杂芳基酰胺类TGR5激动剂化合物、其药学上可接受的盐、其酯、其立体异构体或前药，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、X1、X2、X3和Y如说明书中所定义；本发明还涉及这些化合物的制备方法、药物制剂、药物组合物以及这些化合物在制备治疗和/或预防与TGR5活性调节有关的疾病中的用途。
• [EN] 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] DÉRIVÉS DE 4-FLUORO-(4-(4-BENZYL)PIPÉRIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)MÉTHANONE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QU'INHIBITEURS DE CYP46A1 POUR LE TRAITEMENT D'AFFECTIONS NEURODÉGÉNÉRATIVES
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2022115620A1

  公开（公告）日：2022-06-02

  The present invention refers to 4-Fluoro-(4-(4-Benzyl)piperidin-l-yl) (2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds of formula (I) as CYP46A1 inhibitors for the treatment of neurodegenerative disorders, epilepsy, developmental and epileptic encephalopathies, psychiatric disorders, and spasms; Neurodegenerative disorders such as e.g. Alzheimer's disease, mild cognitive impairment, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, cerebral infarction, glaucoma, and multiple sclerosis; Psychiatric disorders such as e.g. schizophrenia, autism spectrum disorder, delusional disorder, schizoaffective disorder, and depression. An exemplary compound is e.g. (4-fluoro-4-(4-fluorobenzyl) piperidin-l-yl)(2-(py rim idin-4-yl)py rid in-3-y I) methanone (example 3, compound 1).

  本发明涉及公式（I）的4-氟-（4-（4-苄基）哌啶-1-基）（2-（嘧啶-4-基）吡啶-3-基）甲酮衍生物和类似化合物作为CYP46A1抑制剂，用于治疗神经退行性疾病、癫痫、发育性和癫痫性脑病、精神障碍和痉挛；神经退行性疾病，例如阿尔茨海默病、轻度认知障碍、亨廷顿病、帕金森病、肌萎缩性侧索硬化症、创伤性脑损伤、脑梗死、青光眼和多发性硬化症；精神障碍，例如精神分裂症、自闭症谱系障碍、妄想症、情感性精神障碍和抑郁症。一个示例化合物是例如（4-氟-4-（4-氟苄基）哌啶-1-基）（2-（嘧啶-4-基）吡啶-3-基）甲酮（示例3，化合物1）。
• UBE2K modulators and methods for their use
  申请人：Berg LLC

  公开号：US11091447B2

  公开（公告）日：2021-08-17

  Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

  提供的是式 (I) 化合物： 及其药学上可接受的盐类和组合物，可用于治疗与 UBE2K 调节相关的疾病。

表征谱图